Karen Selk is an Endocrinology/Metabolic physician affiliated with UPMC Health System. OpenAlex indexes 27 publications with 326 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1400 Locust St Ste 5120
Suite 5120
Pittsburgh, PA 152195114
Telephone
412-232-9150Registry record last updated 25 Mar 2021.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20252 payments
- Regeneron Pharmaceuticals, Inc.Program year20251 payment
- Amgen Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
62.5%GLP-1 receptor agonist21.3%Trulicity33%Mounjaro31%Ozempic29%Wegovy3%Victoza 3-Pak3%Part D<11 patientsInsulin Analog19.2%Lantus Solostar45%Humalog Kwikpen U-10023%Basaglar Kwikpen U-1009%Toujeo Max Solostar6%Novolog Flexpen5%Lyumjev Kwikpen U-1004%Novolog4%Tresiba Flextouch U-1004%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
19.6%l-Thyroxine12.2%Levothyroxine Sodium68%Synthroid32%Part D≥39 patientsThyroid Hormone Synthesis Inhibitor4.9%Methimazole100%Part D≥13 patients+ 2 more classes in this area
Cardiovascular
13.2%Statin9.7%Atorvastatin Calcium45%Rosuvastatin Calcium37%Pravastatin Sodium18%Part D<11 patientsCholesterol absorption inhibitor1.6%Ezetimibe100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- MON-809 "Strengthening Bones, Supporting Lives: Romosozumab in Osteoporosis Management for Marfan Syndrome"
Journal of the Endocrine Society
2025 - 6574 Pheochromocytoma In A Patient With ESRD; Clinical Challenges And Lessons From A Successful Evaluation
Journal of the Endocrine Society
2024 - 8079 PPI Breaks a Leg! An Unusual Case of Atypical Femur Fracture
Journal of the Endocrine Society
2024 - 7655 Genetic Mysteries Unveiled: Unusual Mutation Unraveled In Hypophosphatasia
Journal of the Endocrine Society
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Marshall W. Webster
UPMC Health System
Debra M. Montrose
UPMC Health System
Charles Atwood, MD
UPMC Health System
Gail Edelsohn, MD
UPMC Health System
Yousef Saleh Khader
Jordan University of Science and Technology
Jens Juul Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Christos Mantzoros, MD
Harvard Medical School
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”